G1 Therapeutics, Inc. Common Stock
GTHX
GTHX was delisted on the 17th of September, 2024.
93 hedge funds and large institutions have $525M invested in G1 Therapeutics, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 39 increasing their positions, 30 reducing their positions, and 37 closing their positions.
30% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 30
19% less funds holding
Funds holding: 115 → 93 (-22)
59% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 37
62% less capital invested
Capital invested by funds: $1.39B → $525M (-$864M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$21M |
| 2 |
JP Morgan Chase
New York
|
+$18.7M |
| 3 |
State Street
Boston,
Massachusetts
|
+$14.7M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$13.5M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$13.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
-$49.6M |
| 2 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$25.4M |
| 3 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$24.8M |
| 4 |
DM
Deerfield Management
New York
|
-$15M |
| 5 |
MCM
Marsico Capital Management
Denver,
Colorado
|
-$10.6M |
GTHX Hedge Fund Activity: Q4 2018 in Review
93 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q4 2018, worth a combined $525M — down 62% from $1.39B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of GTHX and 15 opened new positions — a net loss of 22 holders — while 30 trimmed existing stakes and 39 added.
The largest buyer was Wellington Management Group, adding an estimated $21M. The largest seller was Hillhouse Investment Management, exiting entirely with an estimated $49.6M sold.
- 93 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q4 2018, down from 115 in Q3 2018.
- Funds reported $525M of G1 Therapeutics, Inc. Common Stock stock for Q4 2018, down 62% quarter-over-quarter.
- 15 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q4 2018 and 37 closed out, a net change of -22 holders.
- The largest G1 Therapeutics, Inc. Common Stock buyer in Q4 2018 was Wellington Management Group, an estimated $21M added.
- The largest G1 Therapeutics, Inc. Common Stock seller in Q4 2018 was Hillhouse Investment Management, an estimated $49.6M sold.
Based on aggregated 13F filings for Q4 2018.